Table 2:

Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on antibody concentrations 6 months after the second dose, and antibody half-lives following the second dose

Variablea	Logio antibody concentration 6 mo after 2nd doseb			Antibody half-lives after the 2nd dosec
	Estimate	95% CI	p-value	Estimate	95% CI	p-value
HIV infection	−0.036	−0.19 to 0.11	0.64	6.33	−19.92 to 32.59	0.63
Age (per year)	0.000019	−0.0043 to 0.0043	0.99	0.53	−0.12 to 1.17	0.11
Male sex	−0.059	−0.19 to 0.072	0.37	9.36	−12.83 to 31.54	0.41
White ethnicity	−0.0078	−0.13 to 0.11	0.90	−7.03	−26.97 to 12.90	0.49
# Chronic conditions (per additional)	−0.028	−0.11 to 0.056	0.51	−7.58	−21.67 to 6.51	0.29
Dual ChAdOx1 as initial regimen	−0.94	−1.39 to −0.49	<0.0001	2.84	−76.02 to 81.70	0.94
Interval between first and second doses (per day)	0.0024	−0.00036 to 0.0052	0.087	−0.17	−0.63 to 0.29	0.47
Days since second dose	0.012	0.0033 to 0.020	0.0067	-	-	-
Prior COVID-19	0.50	0.35 to 0.65	<0.0001	-	-	-

^aDashes indicate variables not included in the model

^bquantified using the Roche Elecsys anti-S assay

^cCalculated from all participants with a complete longitudinal data series following the second dose with no values above the ULOQ, and no evidence of prior COVID-19